<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase II:  An innovative ablation device for treating atrial fibrillation</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>09/15/2011</AwardEffectiveDate>
<AwardExpirationDate>01/31/2016</AwardExpirationDate>
<AwardTotalIntnAmount>499400.00</AwardTotalIntnAmount>
<AwardAmount>1060044</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Ruth Shuman</SignBlockName>
<PO_EMAI>rshuman@nsf.gov</PO_EMAI>
<PO_PHON>7032922160</PO_PHON>
</ProgramOfficer>
<AbstractNarration>This Small Business Innovation Research Phase II project proposes to develop a novel ablation balloon catheter to perform radiofrequency ablation on atrial fibrillation patients. The intellectual merit of this project is in its use of an innovative approach to positioning, mapping, and ablation for atrial fibrillation patients, negating the need for excessive catheter rotations and/or serial point ablations.   This new technology significantly reduces user variability, procedural time, and the resultant cost burden on the hospital, physician, insurance payer, and patient.  The research objectives for this project are to design and develop an improved prototype that enables verification of balloon-to-tissue contact; design and develop a 2nd generation radiofrequency generator capable of powering 20 electrodes; refine catheter design to increase reliability/robustness and sheathing capability; and develop 2nd generation handle that allows for the balloon extension.  All of these changes will be validated through in vitro and in vivo testing. &lt;br/&gt;&lt;br/&gt;The broader impact/commercial potential of this project is an improvement in the treatment of atrial fibrillation, which is the most common heart rhythm disturbance encountered in clinical medicine, accounting for 1/3 of hospital admissions for cardiac rhythm disturbances. It is estimated that nearly 2.6 million individuals are currently afflicted with atrial fibrillation in the United States, with a projected increase to nearly 4.4 million people by the year 2030. Given the significant public health and economic impact of atrial fibrillation, there is an urgent need for practical and cost-effective approaches to treat atrial fibrillation.  This technology aims to answer this need, providing an improved method of treatment for patients as well as highly-marketable technology that will save hospitals time and costs burdens.</AbstractNarration>
<MinAmdLetterDate>09/12/2011</MinAmdLetterDate>
<MaxAmdLetterDate>06/01/2015</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>0</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>1127549</AwardID>
<Investigator>
<FirstName>Amr</FirstName>
<LastName>Salahieh</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Amr Salahieh</PI_FULL_NAME>
<EmailAddress>amr@shifamed.com</EmailAddress>
<PI_PHON>4085406251</PI_PHON>
<NSF_ID>000552717</NSF_ID>
<StartDate>09/12/2011</StartDate>
<EndDate>03/17/2012</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Claudio</FirstName>
<LastName>Argento</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Claudio Argento</PI_FULL_NAME>
<EmailAddress>cargento@shifamed.com</EmailAddress>
<PI_PHON>4085406251</PI_PHON>
<NSF_ID>000616439</NSF_ID>
<StartDate>03/17/2012</StartDate>
<EndDate>03/01/2014</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Joann</FirstName>
<LastName>Heberer</LastName>
<PI_MID_INIT>T</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Joann T Heberer</PI_FULL_NAME>
<EmailAddress>jheberer@shifamed.com</EmailAddress>
<PI_PHON>4086372154</PI_PHON>
<NSF_ID>000667030</NSF_ID>
<StartDate>03/01/2014</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Apama Medical, Inc.</Name>
<CityName>Saratoga</CityName>
<ZipCode>950705227</ZipCode>
<PhoneNumber>4085406251</PhoneNumber>
<StreetAddress>18729 METLER CT</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<StateCode>CA</StateCode>
<CONGRESSDISTRICT>18</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>CA18</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>831299305</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>APAMA MEDICAL, INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[Apama Medical, Inc.]]></Name>
<CityName/>
<StateCode>CA</StateCode>
<ZipCode>950705227</ZipCode>
<StreetAddress/>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>18</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>CA18</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5373</Code>
<Text>SBIR Phase II</Text>
</ProgramElement>
<ProgramReference>
<Code>116E</Code>
<Text>RESEARCH EXP FOR UNDERGRADS</Text>
</ProgramReference>
<ProgramReference>
<Code>1491</Code>
<Text>BIOTECH, BIOCHEM &amp; BIOMASS ENG</Text>
</ProgramReference>
<ProgramReference>
<Code>165E</Code>
<Text>SBIR Phase IIB</Text>
</ProgramReference>
<ProgramReference>
<Code>5345</Code>
<Text>BIOMEDICAL ENGINEERING</Text>
</ProgramReference>
<ProgramReference>
<Code>5373</Code>
<Text>SMALL BUSINESS PHASE II</Text>
</ProgramReference>
<ProgramReference>
<Code>8038</Code>
<Text>Biotechnology</Text>
</ProgramReference>
<ProgramReference>
<Code>9102</Code>
<Text>WOMEN, MINORITY, DISABLED, NEC</Text>
</ProgramReference>
<ProgramReference>
<Code>9231</Code>
<Text>SUPPL FOR UNDERGRAD RES ASSIST</Text>
</ProgramReference>
<ProgramReference>
<Code>9251</Code>
<Text>REU SUPP-Res Exp for Ugrd Supp</Text>
</ProgramReference>
<Appropriation>
<Code>0111</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0112</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0113</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0114</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0115</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2011~499400</FUND_OBLG>
<FUND_OBLG>2012~16000</FUND_OBLG>
<FUND_OBLG>2013~12800</FUND_OBLG>
<FUND_OBLG>2014~515844</FUND_OBLG>
<FUND_OBLG>2015~16000</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p>Atrial fibrillation is the most common heart rhythm disturbance encountered in clinical medicine, accounting for one-third of hospital admissions for cardiac rhythm disturbances. It is estimated that nearly 2.6 million individuals are currently afflicted with atrial fibrillation in the U.S., with a projected increase to nearly 4.4 million people by the year 2030. Given the significant public health and economic impact of atrial fibrillation, there is an urgent need for practical and cost-effective approaches to treat the condition. This has, in fact, led to the recent inclusion of atrial fibrillation as one of the top recommended healthcare research priorities in a recent Institute of Medicine report.</p> <p>This Small Business Innovation Research (SBIR) project developed a novel ablation balloon catheter to perform radiofrequency ablation on atrial fibrillation patients. Designed with a conformable balloon with 18 ablation electrodes painted on the surface, the device can leverage the clinical advantages of catheter ablation while significantly reducing user variability, procedural time, and the resultant cost burden on the hospital, physician, insurance payer, and patient. Unlike currently available ablation systems, Apama&rsquo;s system provides a proprietary means of positioning, mapping and ablation with a single device, delivering complete pulmonary vein isolation (PVI) with a single catheter placement, thus negating the need for excessive catheter rotations and/or serial point ablations.</p> <p>Under this project, Apama Medical designed and developed an improved prototype that enables visualization of balloon-to-tissue contact; designed and developed a second-generation radiofrequency generator capable of powering 20 electrodes; refined catheter design to increase reliability/robustness and sheathing capability; and developed a second-generation handle that allows for the balloon extension. The ablation balloon catheter was validated in pig studies. Apama has created a reliable radiofrequency balloon catheter system that can be delivered to the cardiac chamber and create continuous lesions with a single application.</p><br> <p>            Last Modified: 05/19/2016<br>      Modified by: Joann&nbsp;T&nbsp;Heberer</p> </div> <div class="porSideCol"></div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[ Atrial fibrillation is the most common heart rhythm disturbance encountered in clinical medicine, accounting for one-third of hospital admissions for cardiac rhythm disturbances. It is estimated that nearly 2.6 million individuals are currently afflicted with atrial fibrillation in the U.S., with a projected increase to nearly 4.4 million people by the year 2030. Given the significant public health and economic impact of atrial fibrillation, there is an urgent need for practical and cost-effective approaches to treat the condition. This has, in fact, led to the recent inclusion of atrial fibrillation as one of the top recommended healthcare research priorities in a recent Institute of Medicine report.  This Small Business Innovation Research (SBIR) project developed a novel ablation balloon catheter to perform radiofrequency ablation on atrial fibrillation patients. Designed with a conformable balloon with 18 ablation electrodes painted on the surface, the device can leverage the clinical advantages of catheter ablation while significantly reducing user variability, procedural time, and the resultant cost burden on the hospital, physician, insurance payer, and patient. Unlike currently available ablation systems, ApamaÃ†s system provides a proprietary means of positioning, mapping and ablation with a single device, delivering complete pulmonary vein isolation (PVI) with a single catheter placement, thus negating the need for excessive catheter rotations and/or serial point ablations.  Under this project, Apama Medical designed and developed an improved prototype that enables visualization of balloon-to-tissue contact; designed and developed a second-generation radiofrequency generator capable of powering 20 electrodes; refined catheter design to increase reliability/robustness and sheathing capability; and developed a second-generation handle that allows for the balloon extension. The ablation balloon catheter was validated in pig studies. Apama has created a reliable radiofrequency balloon catheter system that can be delivered to the cardiac chamber and create continuous lesions with a single application.       Last Modified: 05/19/2016       Submitted by: Joann T Heberer]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
